SCHEMBL144459 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	ABCB1	P08183	1/20	0.50

▸	ABCG2	Q9UNQ0	1/20	0.50

▸	PDE4B	Q07343	3/20	0.49

▸	NPC1	O15118	3/20	0.47

▸	POLB	P06746	1/20	0.47

▸	MAPK1	P28482	2/20	0.47

▸	SMN1; SMN2	Q16637	3/20	0.47

▸	MAPT	P10636	2/20	0.47

▸	HTT	P42858	1/20	0.47

▸	RAB9A	P51151	3/20	0.47

▸	TP53	P04637	1/20	0.47

▸	LMNA	P02545	2/20	0.46

▸	AAK1	Q2M2I8	3/20	0.46

▸	ALDH1A1	P00352	1/20	0.46

▸	GAA	P10253	1/20	0.46

▸	PDE4A	P27815	1/20	0.45

▸	PDE4C	Q08493	1/20	0.45

▸	PDE4D	Q08499	1/20	0.45

▸	PDE3B	Q13370	1/20	0.45

▸	PDE3A	Q14432	1/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL145502	0.93	ABCG2 (0.56)	ABCB1ABCG2PDE4BNPC1MAPK1
SCHEMBL146176	0.92	PDE4B (0.50)	ABCB1ABCG2PDE4BNPC1MAPK1
SCHEMBL6684268	0.91	LMNA (0.53)	PDE4BNPC1POLBMAPK1SMN1; SMN2
SCHEMBL6661177	0.88	CCR5 (0.49)	PDE4BNPC1POLBSMN1; SMN2RAB9A
SCHEMBL6844123	0.87	PDE4B (0.47)	PDE4BNPC1POLBMAPK1SMN1; SMN2
SCHEMBL147709	0.87	AAK1 (0.50)	ABCB1PDE4BNPC1POLBMAPK1
SCHEMBL6659876	0.87	SMN1; SMN2 (0.54)	PDE4BNPC1SMN1; SMN2MAPTRAB9A
SCHEMBL142692	0.87	PDE4B (0.63)	ABCB1ABCG2PDE4BNPC1POLB
SCHEMBL149883	0.86	PDE4B (0.53)	ABCB1ABCG2PDE4BNPC1POLB
SCHEMBL6685859	0.85	PDE4B (0.46)	PDE4BNPC1POLBMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	MERK PANTENT GMBH (DE)	2005-03-31	—	—	US	claimed
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	MERCK PATENT GMBH (DE)	2004-12-23	—	—	US	claimed
EP-1368035-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GmbH (DE)	2003-12-10	—	—	EP	claimed
WO-2002072103-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GMBH (DE)	2002-09-19	—	—	WO	claimed
US-20140221455-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	Verva Pharmaceuticals, Inc. (AU)	2014-08-07	—	—	US	disclosed
US-20120059047-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	VERVA PHARMACEUTICALS PTY LTD (AU)	2012-03-08	—	—	US	disclosed
US-20050282733-A1	Differentiation modulating agents and uses therefor	VERVA PHARMACEUTICALS PTY LTD (AU)	2005-12-22	—	—	US	disclosed
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	MERK PANTENT GMBH (DE)	2005-03-31	—	—	US	disclosed
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	MERCK PATENT GMBH (DE)	2004-12-23	—	—	US	disclosed
US-20040235845-A1	Use of phosphodiesterase iv inhibitors	MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE)	2004-11-25	—	—	US	disclosed
EP-1463509-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GmbH (DE)	2004-10-06	—	—	EP	disclosed
EP-1435958-A1	USE OF PHOSPHORODIESTERASE IV INHIBITORS	MERCK PATENT GmbH (DE)	2004-07-14	—	—	EP	disclosed
EP-1368035-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GmbH (DE)	2003-12-10	—	—	EP	disclosed
WO-2003037349-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GMBH (DE)	2003-05-08	—	—	WO	disclosed
WO-2003032993-A1	USE OF PHOSPHORODIESTERASE IV INHIBITORS	MERCK PATENT GMBH (DE)	2003-04-24	—	—	WO	disclosed
EP-0763534-B1	Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors	MERCK PATENT GMBH (DE)	2003-02-26	—	—	EP	disclosed
WO-2002072103-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GMBH (DE)	2002-09-19	—	—	WO	disclosed
US-5859008-A	Arylalkyl diazinones	MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE)	1999-01-12	—	—	US	disclosed
EP-0763534-A1	Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors	MERCK PATENT GmbH (DE)	1997-03-19	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120059047-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	FGF1, FABP4, FGF2	ABCB1 4804/4885ABCG2 4770/4885PDE4B 1040/4885
US-20040235845-A1	Use of phosphodiesterase iv inhibitors	PDE4A, PDE3A, PDE3B	ABCB1 1255/4885ABCG2 952/4885PDE4B 4/4885
US-20050282733-A1	Differentiation modulating agents and uses therefor	FGF1, FABP4, FGF2	ABCB1 4804/4885ABCG2 4770/4885PDE4B 1040/4885
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	PDE4A, PDE4B, PDE12	ABCB1 1476/4885ABCG2 2694/4885PDE4B 2/4885
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	PDE4A, PDE4B, PDE4C	ABCB1 1138/4885ABCG2 1594/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.